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Abstract
We develop a variable population age-structured ODE model to investigate the role of
Intermittent Preventive Treatment (IPT) in averting malaria-induced mortalities in children, as
well as its related cost in promoting the spread of anti-malarial drug resistance. IPT, a malaria
control strategy in which a full curative dose of an antimalarial medication is administered to
vulnerable asymptomatic individuals at specified intervals, has been shown to have a positive
impact on reducing malaria transmission and deaths in children and pregnant women. However,
it can also promote drug resistance spread. Our mathematical model is used to explore IPT
effects on drug resistance in holoendemic malaria regions while quantifying the benefits in deaths
averted. Our model includes both drug-sensitive and drug-resistant strains of the parasite as
well as interactions between human hosts and mosquitoes. The basic reproduction numbers for
both strains as well as the invasion reproduction numbers are derived and used to examine the
role of IPT on drug resistance. Numerical simulations show the individual and combined effects
of IPT and treatment of symptomatic infections on the prevalence levels of both parasite strains
and on the number of lives saved. The results suggest that while IPT can indeed save lives,
particularly in the high transmission region, certain combinations of drugs used for IPT and
drugs used to treat symptomatic infection may result in more deaths when resistant parasite
strains are circulating. Moreover, the half-lives of the treatment and IPT drugs used play an
important role in the extent to which IPT may influence the rate of spread of the resistant
strain. A sensitivity analysis indicates the model outcomes are most sensitive to the reduction
factor of transmission for the resistant strain, rate of immunity loss, and the clearance rate of
sensitive infections.
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1 Introduction
Malaria continues to be a burden in many parts of the world, especially in the African continent.
An estimated 214 million new malaria cases (range 149-303 million) were reported worldwide
in 2015, with Africa contributing the most, about 88%, followed by South-East Asia and the
Eastern Mediterranean region, each contributing 10% and 2%, respectively [32]. The estimated 2015
worldwide number of deaths was 438, 000, a decline from the 2012 estimates. Of these deaths, 90%
came from the African region, 7% from South-East Asia and 2% from the Eastern Mediterranean
region [30, 32, 33]. Although malaria mortality rates are dropping (down by 60% worldwide between
2000 and 2015), many people still suffer the burdens of illness, infection and death, with children
under five more susceptible to these burdens. In fact, the 2015 globally estimated under five deaths
was 306, 000 [32]. Thus, strategies for reducing infection and disease burden in infants and children,
groups bearing the highest burden of the disease, are increasingly urgent. Intermittent Preventive
Treatment (IPT) is one such strategy employed.
IPT is a preventative malaria control strategy used as a tool to reduce disease burden and
death among infants, children and pregnant women [13]. During IPT, these vulnerable humans
are given a full curative antimalarial medication dose regardless of their infection status. IPT has
been shown to be efficacious in reducing malaria incidence and burden in pregnant women, infants
and children [10, 17, 20, 29]. In particular, its use in pregnant women (via IPTp) with the drug
Sulfadoxine-pyrimethamine (SP) was shown to be efficacious [10, 20, 29]. In infants (via IPTi)
and children (via IPTc), with the combination drug Sulfadoxine-pyrimethamine plus amodiaquine
(SP+AQ), it was shown to be efficacious in reducing malaria incidence and burden [17, 20], with
significant protection for children sleeping under insecticide-treated bednets (ITNs) [17, 20].
Although IPT (IPTp, IPTi, IPTc) as a malaria control strategy has been shown to have positive
impact in averting disease deaths in IPT treated individuals, it faces challenges due to the emergence
of resistance to the drugs used for IPT treatment [10, 13]. Thus understanding the interacting
relationship between IPT use as a control strategy and the emergence and rate of spread of drug
resistance is important. Previous modeling studies have shown that IPTi/IPTc is likely to accelerate
drug resistance spread [23, 25, 28]. Teboh-Ewungkem et al. in [28] found that while treatment
of symptomatic infections is the main driver for drug resistance, IPT can increase drug-resistant
malaria, particularly when a long half-life drug such as SP is used. The IPT treatment schedule can
also affect the intensity of acceleration, with a critical threshold above which drug resistant invasion
is certain.
The models used to examine the role of IPT in drug resistance did not consider the direct
benefits of IPT in deaths (and/or cases) averted [23, 25, 28]. In order to better understand the
trade off between deaths averted and increasing drug resistance, we adapted the Teboh-Ewungkem
et al. 2015 [28] model to include age structure, death due to disease, and high or low transmission
regions with year-round transmission. This allowed us to quantify the relative impact of IPT and
inform strategies for using IPT that will maximize number of deaths averted while minimizing
resistance. In particular, we considered the following quantities of interest: number of deaths
averted by IPT, ratio of sensitive to resistant strains in the population across time, total number of
malaria deaths, basic reproduction number, and invasion reproduction number. Our goals were to
(1) determine the critical level of IPT treatment that would minimize the spread of drug resistance
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and maximize the positive impact in lives saved; (2) determine the role of IPT in saving lives and
potentially facilitating drug resistance for low and high transmission regions; and (3) understand
the relative roles of symptomatic treatment and IPT in the establishment of drug resistant strains
of malaria while also considering partial resistance. In order to explicitly consider the sustainability
of particular approaches, we modeled our time-varying quantities of interest for 1, 5, and 10 years.
Our model differs from that of O’Meara et al. [23] and Teboh-Ewungkem et al. [25] in that the
transmission dynamics of the vector population are explicitly modeled as well as age structure for
the human hosts. The model explicitly accounted for humans with different levels of immunity as
well as incorporated the dynamics of the resistant malaria strain.
The paper is divided as follows: Section 2 describes the model, giving the associated variables
and parameters, while Section 3 gives a detailed analysis of the disease-free, non-trivial boundary,
and endemic equilibria of the model. In Section 4, we present the model results and associated
figures, with a parameter sensitivity analyses carried out in Section 5. Section 6 then gives a
discussion and conclusion. We found that although IPT treatment can increase the levels and
timing of resistant strain invasion, treatment of symptomatic individuals plays a much larger role in
promoting resistance under our assumptions and parameter values. We also found that the resistant
strain is highly sensitive to the half-life of the drug being administered. Successful establishment
of the resistant strain is more likely when the drug being used for IPT and treatment has a long
half-life. Finally, in the the scenario where the symptomatic treatment drug has a short half-life and
low or little resistance to the treatment drug is present in the circulating malaria strains, then using
SP as an IPT drug in high transmission regions will result in many lives saved without significantly
increasing resistance levels. It should be noted, however, that if strains with high resistance to the
symptomatic treatment drug and the IPT drug emerge, then IPT could drive higher resistance
proportions and result in an increase in number of deaths. Therefore, close monitoring of resistant
strains is suggested by our model when IPT is in use.
2 Description of the Model
Our mathematical model of the transmission dynamics of the malaria parasite takes into account
the following three interacting components of the parasite’s life cycle: (1) the parasite that causes
the disease, (2) the human hosts who can be infected by the parasite, and (3) the vector hosts
(mosquitoes) that transmits the disease from one human to another. The model incorporates the
use of IPT and symptomatic treatment employed in the human population. Humans infected with
the transmissible forms of the parasites could carry parasites that are either sensitive or refractory
(resistant) to drugs used to treat the malaria infection, or drugs used as chemoprophylaxis via IPT.
The model developed expands the model in Teboh-Ewungkem et al. 2015 [28] to include explicit
age structure and disease-induced mortalities in the human populations. We consider scenarios with
non-seasonal high transmission as well as low transmissions. Model flow diagrams are shown in
Figures 1, 2 and 3, while the definitions of the variables and parameters are given in Tables 1, 2,
and 3.
The model utilized is a nonlinear deterministic age-structured variable-population model described
by a system of ordinary differential equations with IPT usage incorporated. In the model, the human
population is split into two main groups: (1) juveniles with naive or no clinical immunity, and (2)
mature humans who have a higher level of clinical immunity to malaria, due to frequent exposure to
the parasites [16, 25]. By clinical immunity, we mean the gradual acquisition of parasite-exposed-
primed immune response enabling an individual to be symptom-free even though they might have
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the transmissible forms of the parasites in their blood stream [7]. Thus mature humans, those
considered to have higher immune levels, usually do not feel sick from the malaria parasite infection
[16, 25], which can be associated with less severe malaria symptoms. Thus the rates of anti-malarial
drug use among mature individuals will be considered to be lower [16, 25].
Thus juveniles, the infants and children, are those receiving IPTi or IPTc, respectively, while
mature individuals do not receive any form of IPT. Typically, the population of juveniles will
consist of the 0− 5 years old age group. However, this age group can be extended or made shorter
depending on the transmission intensity of the region (low or high) and/or whether the region has
stable or unstable transmission with transmission either occurring all year round (holoendemicity)
or intermittently with periods of intense transmission (hyperendemicity) [15]. For example, for
a region with high malaria transmission intensity, we consider mature humans to be those who
have been repeatedly re-exposed to the malaria parasite and thus have developed a more superior
immunity [16, 25]. We consider that age group to be the > 5 years old group. We note, however
that, even within the same endemic country, there might be regions of high transmission intensity
or low transmission intensity depending on whether the region is a highland or lowland region or a
rural or urban region. Foe example, the Kenyan highland has low transmission and the Kenyan
lowland has high transmission. In addition, the urban city of Nairobi in Kenya is considered to be
a low transmission region while Lake Victoria, a rural area, is considered be a high transmission
region [25].
In our model, both the juvenile and mature human populations are subdivided into mutually
exclusive compartments categorized by their malaria strain-type disease infection or treatment
status. In our presentation below, we will refer to IPTi and IPTc as just IPT. Then compartments
for the juveniles at any time t are: susceptible juveniles (denoted by S), symptomatic juveniles
infected with the sensitive strain (Is) or the resistant strain (Js), asymptomatic juveniles infected
with the sensitive strain (Ia) or the resistant strain (Ja), susceptible juveniles who’ve received
IPT (T ), asymptomatic infected juveniles who received IPT (Ta), treated symptomatic infected
juveniles (Ts) and the temporarily immune juveniles (R), see Figure 1. As juveniles age, they
join a corresponding mature human population class (see Figure 2). Denoting the corresponding
mature human classes by the subscript m, the compartments for the mature human population
at time t are: susceptible individuals (Sm), symptomatic infected with the sensitive strain (Ims)
or the resistant strain (Jms), asymptomatic individuals infected with the sensitive strain (Ima) or
the resistant strain (Jma), uninfected juveniles who received IPT and aged, aging into the mature
class (Tm), infected asymptomatic juveniles who received IPT and aged, aging into the mature
class (Tma), treated symptomatic infected humans (Tms) and temporarily immune humans (Rm),
see Figure 3. Additionally, at any time t, there are a number Sv (susceptible mosquitoes) and M
(infectious mosquitoes) that define the mosquito classes. The M mosquitoes are further sub-divided
into subclasses Mr and Ms which determines the type of parasite they are infected with, sensitive
or resistant. Thus the total mosquito population at time t, denoted by Nv is Nv = Sv +Mr +Ms.
A detailed description of all the variable classes are given in Table 1.
When a susceptible human comes in contact with an infectious mosquito, the human may
become infected at a certain rate, βh, following a standard incidence infection term. Some of those
infected humans may show symptoms while others may not. Hence the split of the infected human
class (considered here to be those with the parasite in their blood stream with the potential to
infect a mosquito) into two subgroups: the asymptomatic subgroup (identified by the subscript a
and considered to be those who do not show clinical symptoms), and the symptomatic subgroup
(identified by the subscript s). We consider that a proportion of the susceptible individuals (λ for
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the juveniles and λ′ for the mature individuals) may show symptoms upon infection, while the
remaining proportion (1 − λ for the for the juveniles and 1 − λ′ for the mature individuals) are
assumed to be asymptomatic. We note that the population of mature asymptomatic individuals is
typically much larger than that for the juveniles in high transmission areas because of higher levels
of clinical immunity to malaria for these mature individuals due to their frequent exposure to the
parasites [16, 25] which enables them to be symptom-free even when they have parasites in their
blood stream [7, 16, 25]. Thus we will expect λ > λ′ in a high transmission region, but to be of
similar size in a low transmission region.
Additionally, contact between an infected mosquito and a susceptible human may lead to the
human being infected with the sensitive parasite strain, identified by the variable I, if their bite
came from an Ms-type mosquito, or a resistant parasite strain, identified by the variable J , if their
bite came from an Mr-type mosquito. It is possible for the strains to differ in fitness, noted by κh,
the fitness difference for the resistant strain. The factor κh multiplies the transmission terms for
individuals (whether mosquito or human) infected with the resistant strain. We assume 0 ≤ κh ≤ 1.
In summary, an infectious human, naive or mature -immune, may be symptomatic and infected with
the sensitive parasite strain (classes Is and Ims), or the resistant parasite strain (classes Js and
Jms), or asymptomatic and infected with the sensitive parasite strain (classes Ia and Ima), or the
resistant parasite strain (classes Ja and Jma). We note that we do not consider co-infection in our
model. Thus any individual co-infected with the sensitive or resistant parasite strain is considered a
resistant infectious human.
In our model, we assume that only the symptomatic humans (juveniles or mature) will seek treat-
ment. In particular, we assume that symptomatic naive-immune individuals clear their symptomatic
parasite infections only via treatment else they will die from the infection (thus all symptomatic
children who do not die of the disease receive treatment). This assumption is related to the less
developed immune system for these individuals. On the other hand, in addition to treatment,
symptomatic mature-immune individuals can also clear their parasite naturally, because of their
developed immune response. Symptomatic individuals who do not clear their infections via treatment
or naturally (for the case of mature-immune humans) can die due to the disease. This death rate
differs between naive-immune, δ, and mature-immune, δm. Typically, the disease-induced death rate
for the naive-immune individuals is much higher than for the mature individuals [11], up to 10 folds
higher. Thus, we will assume that δ > δm.
The baseline drugs considered for treatment of symptomatic malaria infections are WHO
recommended combination therapy drugs such as Artemether-lumefantrine (also called Coartem, to
be referred henceforth as the AL drug) or other approved Artemisinin-based combination therapy
drugs (ACT drugs) [31, 32]. However, we will investigate the impact of a long half-life drug such as
sulphadoxine-pyrimethamine (SP) as a treatment drug for symptoms. If a symptomatic individual
infected with the sensitive parasite strain receives treatment, they move to the treatment class Ts
for the naive-immune individual or Tms for the mature-immune individual. This occurs at rate a,
where 1/a is the average time from the beginning of the treatment to the clearance of the sensitive
parasite. If the human (naive or mature -immune) is infected with the resistant parasite strain, we
assume that the drug is ineffective against the resistant parasite. Thus such infectious humans, type
Js and Jms individuals, move to their corresponding treatment classes, class Ts, respectively Tms,
at rate pa, where p is measures the efficacy of the drug against a resistant infection. We note that p
can account for full resistance (in which case p = 0) or partial resistance (in which case p > 0). In
addition, mature-immune symptomatic humans can also clear their infection naturally at rate σms,
with a proportion ξm developing temporal immunity to join the temporal immune class R, and the
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remainder 1− ξms instead joining the susceptible mature human class.
Asymptomatic infectious individuals (naive or mature - immune) do not seek treatment because
they do not show symptoms even though considered to be clinically sick and infectious. However,
these naive-immune and mature-immune individuals can clear their parasitic infections naturally
at rate σa and σma, respectively, with a proportion ξ and ξm, respectively, developing temporal
immunity to join the temporal immune classes R and Rm. The remainder, 1− ξ and 1− ξm, instead
join the susceptible naive immune (S) and mature human (Sm) classes. We also assumed that
asymptomatic infectious humans (naive-immune and mature-immune) can develop symptoms at
rates ν and ν′, respectively.
As a preventative measure, both susceptible and asymptomatic naive-immune individuals receive
intermittent preventive treatment (IPT), as was the case in [23, 25, 28]. IPT is administered at a
constant per-capita rate c where 1/c is the average time between IPT treatments. We will use the
WHO recommended drug for IPT treatment, sulphadoxine-pyrimethamine (SP), a long-half life
drug [25, 28, 31, 32] as the baseline IPT treatment drug. Naive-immune juveniles who receive IPT
will move to the IPT treated class T , for the case where the IPT was administered to a susceptible
juvenile, and to the IPT treated class Ta, for the case where the IPT was administered to an
asymptomatic infectious juvenile.
All individuals, mature or naive-immune, who’ve received treatment and are in the treated
classes are assumed to have drugs at therapeutic levels in their system that can clear sensitive
parasites. This is regardless of whether the treatment was due to a symptomatic infection (classes
Ts and Tms individuals), or due to IPT (for the case of naive-immune individuals) classes T and Ta.
As the drug concentration in these treated individuals declines, the treated individuals may either
join the temporarily immune class or the susceptible class. In particular, as the drug concentration
in treated individuals who were treated as a result of a symptomatic infection declines at rate rs,
these treated individuals are assumed to join the temporary immune class (R or Rm) with class Ts
moving to class R and class Tms moving to class Rm. The rate rs is dependent on the half-life of
the drug used for treatment, with 1/rs the time in days the treatment drug reaches levels that do
not have therapeutic effects on a sensitive parasite infection. We’ve assumed here that an immune
response is triggered as a result of malaria symptoms, hence the development of temporary immunity.
For individuals who receive IPT, the rate of decline of the drug in their system is r. If the IPT
was administered to a susceptible naive-immune, generating a type T naive-immune juvenile, the
individual will move to the susceptible class, S, as their drug concentration declines at that rate
r. However, if the IPT was administered to an asymptomatic infectious naive-immune juvenile
generating a type Ta naive-immune juvenile, a proportion b of these treated juveniles will move to
the temporary immune class R, while the remaining proportion 1− b join the susceptible class, S,
both at rate r. The separation is justified in that an asymptomatic infection is as a result of some
naive level of temporal immunity bolstered by the IPT drug. Here 1/r is the time in days the IPT
drug is at levels that do not have therapeutic effects on a sensitive parasite. Temporarily immune
individuals (in classes R and Rm) lose their temporary immune status to join the susceptible class
at a rate ω for naive-immune and ω′ for mature-immune individuals.
We further assume in our model that after age 5, which could be shorter depending on whether
the region is a stable high transmission region, a naive-immune juvenile matures to join an equivalent
corresponding mature class. This maturation happens at a constant per-capita rate of η where
1/η is the age considered for the naive-immune individual to have developed a reasonable immune
response due to repeated re-exposure to the malaria parasite. For naive-immune treated individuals
who received IPT, we assume if they mature while receiving IPT, they move into a temporary IPT
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treatment compartment in the mature group represented by classes Tm and Tma. When the drug
concentration of the individuals in these classes decline at rates r, where r is as earlier defined, they
either join the susceptible mature human class Sm, or the temporary immune mature human class
Rm. If the individuals are coming from class Tm then they will move to class Sm. On the other
hand, If the individuals are coming from class Tma then a proportion bm will move to class Rm
while the remaining proportion 1− bm will move to class Sm. None of the mature humans receive
IPT, and thus there is no movement of mature-immune individuals into class Tm or Tma.
Additionally, we assume that all recruitment via births occur at a constant rate Λh into the
susceptible naive-immune class and that natural death can occur from all compartments at a constant
per-capita death rate of µh for the naive-immune compartments, and a constant per-capita death
rate of µmh for the mature immune individuals. Figure 2 shows the the movement due to maturation
from every naive-immune compartment into the parallel compartment in the mature-immune classes,
indicating where there is disease-induced deaths, natural death and recruitment. The equations
governing the human disease dynamics are given in equations (1b)-(1j) and (2b)-(2j), where equations
(1b)-(1j) model the dynamics of the naive-immune human population, and equations (2b)-(2j) model
that of the mature-immune human population. The total human population as well as the sub total
naive and mature -immune human populations are modeled by equations (3a)-(3c).
When a susceptible mosquito feeds, successfully taking blood from an infectious human, the
mosquito may acquire the malaria parasite from the human at rate βv, moving to either the Ms
or Mr class. If the blood meal was from an infectious human infected with the sensitive parasite
strain, then the mosquito, upon infection, will become a type Ms mosquito, infected with the
sensitive parasite strain. If on the other hand, the blood meal was from an infectious human
infected with the resistant parasite strain, then the mosquito, upon infection, will become a type Mr
mosquito, infected with the resistant parasite strain. Here, we also assume that the transmission
success to mosquitoes by humans infected with the resistant parasite is less than that from humans
infected with the sensitive parasite. Thus, the transmission rate of resistant parasites to susceptible
mosquitoes is κvβv, where 0 < κv < 1 is the transmission reduction factor. We further assume
that a mosquito cannot be co-infected, that is, if a mosquito is infected with a particular strain of
malaria, the mosquito will not acquire nor successfully transmit a second distinct strain of malaria.
Thus there is no movement between the Ms and Mr compartments; once a mosquito is infected,
it remains so until it dies; and natural death occurs from each mosquito compartment at rate µv.
The equations governing the mosquito dynamics are given in equations (4a)-(4c), with the total
mosquito population modeled by equation (5a).
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Figure 1: Transfer diagram for human infection within the naive-immune population. Dashed lines
represent parasite transmission via infected mosquitoes. I infections are with sensitive strains and J
with resistant strains of malaria with subscripts a and s representing asymptomatic and symptomatic
cases. T and Ta are susceptible and asymptomatic individuals, respectively, that received IPT,
while Ts is individuals receiving treatment for a symptomatic case. S is fully susceptible and R is
temporarily immune.
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Figure 2: Transfer diagram between the naive-immune juvenile human population and the mature
human population. Dashed lines represent disease-induced mortality. An average time of 1/η is
spent in the naive-immune class.
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Figure 3: Transfer diagram for human infection within the mature population. Dashed lines represent
parasite transmission via infected mosquitoes. Tma and Tm are holding compartments for individuals
that mature while in an IPT treatment class (so drug is still circulating in their system). The
subscript m indicates immune-mature individuals, but all other notation is the same as in Figure 1.
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Table 1: State variables and their descriptions
Variable Description of Variable
Sv Number of susceptible mosquitoes.
Ms Number of mosquitoes infected with the sensitive strain.
Mr Number of mosquitoes infected with the resistant strain .
S Number of susceptible juveniles.
Is Number of symptomatic infected juveniles infected with the sensitive parasite strain.
Ia Number of asymptomatic infected juveniles infected with the sensitive parasite strain.
Js Number of symptomatic infected juveniles infected with the resistant parasite strain.
Ja Number of asymptomatic infected juveniles infected with the resistant parasite strain.
Ts Number of symptomatic infected juveniles who are treated due to their symptoms.
T Number of susceptible juveniles who’ve received IPT treatment.
Ta Number of asymptomatic infected juveniles who’ve received IPT treatment.
R Number of infected juveniles who clear their parasite either naturally or via treatment
and develop temporary immunity.
Sm Number of susceptible mature humans.
Ims Number of symptomatic infectious mature humans infected with the sensitive strain.
Ima Number of asymptomatic infected mature humans infected with sensitive strain.
Jms Number of symptomatic infected mature humans infected with the resistant strain.
Jma Number of asymptomatic infected mature humans infected with the resistant strain.
Tm Number of susceptible juveniles who had received IPT and aged prior to their drug
levels declining to the levels that rendered them susceptible.
Tma Number of asymptomatic juveniles who had received IPT and aged prior to their drug
levels declining to the levels that rendered them temporary immune or susceptible.
Tms Number of mature humans who receive treatment due to their symptomatic infection.
Rm Number of infected mature humans who clear their parasite either naturally or via
treatment and develop temporary immunity.
Nc Total Number of juvenile population.
Nm Total Number of mature human population.
Nh Total human population.
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dS
dt
= Λh − µhS − βh(Ms + κhMr)S/Nh − cS + (1− ξ)σa(Ia + Ja) (1a)
+ (1− b)rTa + rT + ωR− ηS, (1b)
dIs
dt
= λβhMsS/Nh + νIa − (a+ µh + η + δ)Is, (1c)
dIa
dt
= (1− λ)βhMsS/Nh − (c+ ν + σa + µh + η)Ia, (1d)
dJs
dt
= λκhβhMr[S + Ts + T + Ta]/Nh + νJa − (pa+ µh + η + δ)Js, (1e)
dJa
dt
= (1− λ)κhβhMr[S + Ts + T + Ta]/Nh − (σa + ν + µh + η)Ja, (1f)
dTs
dt
= aIs + paJs − rsTs − κhβhMrTs/Nh − (µh + η)Ts, (1g)
dT
dt
= cS − rT − κhβhTMr/Nh − (µh + η)T, (1h)
dTa
dt
= cIa − rTa − κhβhTaMr/Nh − µhTa − ηTa, (1i)
dR
dt
= rsTs + brTa + ξσa(Ia + Ja)− (ω + µh + η)R, , (1j)
dSm
dt
= ηS − µmhSm − βh(Ms + κhMr)Sm/Nh + (1− ξm)σma(Ima + Jma) (2a)
+ (1− ξm)σms(Ims + Jms) + ω′Rm + rTm + (1− bm)rTma, (2b)
dIms
dt
= ηIs + λ
′βhMsSm/Nh + ν′Ima − (a+ µmh + δm + σms)Ims, (2c)
dIma
dt
= ηIa + (1− λ′)βhMsSm/Nh − (σma + ν′ + µmh)Ima, (2d)
dJms
dt
= ηJs + λ
′κhβhMr[Sm + Tms + Tm + Tma]/Nh + ν′Jma − (pa+ σms + µmh + δm)Jms,
(2e)
dJma
dt
= ηJa + (1− λ′)κhβhMr[Sm + Tms + Tm + Tma]/Nh − (σma + ν′ + µmh)Jma, (2f)
dTms
dt
= ηTs + aIms + paJms − κhβhMrTms/Nh − (µmh + rs)Tms, (2g)
dTm
dt
= ηT − κhβhTmMr/Nh − (µmh + r)Tm, (2h)
dTma
dt
= ηTa − κhβhTmaMr/Nh − (µmh + r)Tma, (2i)
dRm
dt
= ηR+ rsTms + bmrTma + ξmσma(Ima + Jma) + ξmσms(Ims + Jms)− ω′Rm − µmhRm,
(2j)
In our model, the total juvenile population is Nc = S + Is + Ia + Js + Ja + T + Ts + Ta + R,
the total mature population is Nm = Sm + Ims + Ima + Jms + Jma + Tm + Tms + Tma + Rm, so
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that the total human population Nh = Nc +Nm. The equations that model the Nc, Nm and Nh
populations are:
dNc
dt
= Λh − ηNc − µhNc − δ(Is + Js), (3a)
dNm
dt
= ηNc − µmhNm − δm(Ims + Jms), (3b)
dNh
dt
= Λh − µhNc − µmhNm − δ(Is + Js)− δm(Ims + Jms). (3c)
The total human population has a disease-free carrying capacity of N∗h = Λh/(ψµh + (1− ψ)µmh),
where ψNh = Nc is the total naive-immune human population, and (1− ψ)N∗h = N∗m is the total
mature-immune human population and N∗c = Λh/(ν + µh) and N
∗
m = ηNc/µmh are the equilibria of
the juvenile and mature populations without death from malaria. Thus, ψ gives the ratios of naive -
immune to the total human populations so that N∗c +N
∗
m = N
∗
h , the total human population.
The equations that govern the mosquito dynamics are
dSv
dt
= Λv − βv [Ia + Is + Ima + Ims + κv(Ja + Js + Jma + Jms)]Sv/Nh − µvSv, (4a)
dMs
dt
= βv(Ia + Is + Ima + Ims)Sv/Nh − µvMs, (4b)
dMr
dt
= κvβv(Ja + Js + Jma + Jms)Sv/Nh − µvMr, (4c)
where the total mosquito population is Nv = Sv +Ms +Mr and is modeled by the equation
dNv
dt
= Λv − µvNv. (5a)
The total mosquito population is also non-constant, with a disease free carrying capacity of Λv/µv.
We remark that in our model discussions, we consider the number of bites per day a human gets
to be limited by mosquito density, not human density, i.e. every mosquito gets to bite as often as
they desire. Therefore the total number of bites per day is defined as (the number of bites desired
per day by a mosquito) * (total number of mosquitoes) = αNv, where Nv is the total number of
mosquitoes and α is the number of bites per mosquito per day. Thus the number of bites per person
per day is αNv/Nh, where Nh is the total number of humans. See [6] for a discussion of alternative
biting rates as the vector-to-host ratio becomes either very low or very high. Thus, βh is then the
product of the mosquito biting rate (α, or number of bites on humans per mosquito per day) times
the probability that transmission occurs if the bite is from an infectious mosquito (represented by
βhv). On the other hand, βv is the product of the mosquito biting rate (α, or number of bites on
humans per mosquito per day) times the probability that transmission occurs if the bite is on an
infectious individual (represented by βvh).
Table 1 summarizes the state variable descriptions. All parameters, as defined in Tables 2 and
3, are non-negative. Details about their interpretation and values will be presented in Section 2.1.
With non-negative initial conditions, it can be verified that the solutions to the model equations
remain non-negative.
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Table 2: Descriptions and dimensions for parameters related to the natural transmission cycle
Parameter Description Dimension
Λh Total human birth rate humans T
−1
Λv Total mosquito birth rate mosquitoes T
−1
µmh Per Capita death rate of mature humans T
−1
µh Per Capita death rate of juveniles T
−1
δm Malaria disease-induced mortality rate for mature humans T
−1
δ Malaria disease-induced mortality rate for juveniles T−1
µv Natural mosquito death rate T
−1
η Rate of aging, i.e. rate at which juveniles become mature humans
and no longer receive IPT
T−1
βh Transmission rate of sensitive parasites from mosquitoes to humans
(αβhv)
mosquito−1 T−1
βv Transmission rate of sensitive parasites from humans to mosquitoes
(αβvh)
mosquito−1T−1
κh Reduction factor of human transmission rate by the resistant
parasite strain
1
κv Reduction factor of mosquito transmission rate by the resistant
parasite strain
1
λ Fraction of juveniles who become symptomatic upon infection 1
λ′ Fraction of matures who become symptomatic upon infection 1
ω Rate of loss of temporary immunity in juveniles T−1
ω′ Rate of loss of temporary immunity in mature adults T−1
λ Fraction of juveniles who become symptomatic upon infection 1
λ′ Fraction of matures who become symptomatic upon infection 1
ν Rate at which juveniles progress from asymptomatic to symp-
tomatic infections
T−1
ν′ Rate at which mature humans progress from asymptomatic to
symptomatic infections
T−1
σs Rate of naturally clearing a symptomatic infection for juveniles T
−1
σa Rate of naturally clearing an asymptomatic infection for juveniles T
−1
σms Rate of naturally clearing a symptomatic infection for matures T
−1
σma Rate of naturally clearing an asymptomatic infection for matures T
−1
ξ Proportion of asymptomatic juveniles who naturally clear their
infection and develop temporary immunity
1
ξm Proportion of mature humans who naturally clear their infection
and develop temporary immunity
1
δ Disease-induced death rate for juveniles T−1
δm Disease-induced death rate for mature humans T
−1
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Table 3: Descriptions and dimensions for parameters related to symptomatic treatment and IPT
Parameter Description Dimension
1/a Days to clear a sensitive infection after treatment T
c Per Capita rate of IPT treatment administration T−1
1/r Time chemoprophylaxis lasts in IPT treated humans T
1/rs Time chemoprophylaxis lasts in symptomatic treated humans T
b Fraction of asymptomatic infected treated juveniles who become
temporarily immune protected
1
bm Fraction of asymptomatic infected treated mature humans who
become temporarily immune protected
1
p Efficacy of drugs used to clear resistant infections 1
2.1 Parameters
In this section, we present a discussion of the parameters used in the model. The chemoprophylaxis
IPT drug considered here is sulphadoxine-pyrimethamine (SP), a drug with a long half-life (148-256
hours). Drugs with long half-lives are slowly eliminated from the body compared to those with
shorter half-lives, and are therefore expected to impose greater selective pressure for drug resistance
than those with shorter half-lives [2]. The expectation is that drugs that persist longer in the body
at sub-therapeutic levels will provide more opportunities for non-resistant (susceptible) parasites to
acquire resistant traits, and for partially resistant parasites to become fully resistant. Resistance to
SP, a long half-life drug, is common, while resistance to Artemether-lumefantrine (AL ) or other
approved Artemisinin-based combination therapy drugs (ACT), short-half life drugs, has not been
reported in most African countries. Typically, SP, the long half-life drug, is used for IPT, while the
short-half-life drugs ACT or AL are used to treat infections. ACT and AL currently work against
both sensitive and resistant parasites in most regions, so are associated with values of p closer to
1. If resistance develops to these, then the value of p for treatment drugs will be closer to 0. On
the other hand, SP clears sensitive parasites but not resistant parasites. Note that since short
half-life drugs such as ACT and AL at therapeutic levels are effective against resistant parasites, if
we consider their use as IPT drugs, then we may need to add an additional link from Ja to Ta but
with much lower effectiveness. The lower effectiveness against clearance of resistant parasites comes
as a result of the way IPT is administered, with long intervals between administration, allowing
for opportunities for the drug to dip below therapeutic levels between treatments [14]. In this
manuscript, we assume that asymptomatic infection by resistant parasites are untreated, since these
individuals do not seek treatment and for those receiving IPT we assume a negligible impact on
clearance. On the other hand, symptomatic infections by resistant parasites have higher clearance
success rates if treated with an AL or ACT drug, or are partially treatable if treated with SP (this
as a result of symptoms making it possible for the drug to bolster the symptom-initiated body’s
natural and adaptive immune response aiding in parasite clearance 1.
The parameters 1/rs and 1/r, give the respective average time chemoprophylaxis lasts in
symptomatic treated and IPT-treated humans, respectively. These values were estimated based on
reported half-lives values for antimalarial drugs. Omeara et al. in [23] reported that for a drug
1This assumption comes from evidence in [9] suggesting higher success in parasite clearance under some background
immunity. We note, however, that the original study was performed on the rodent malaria Plasmodium chabaudi,
where it was shown that drug-resistant parasites could be cleared in partially immune individuals.
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with a long half-life such as sulfadoxine-pyrimethamine (SP), it takes about 52 days for the drug
concentration to drop below a threshold value that it cannot clear malaria parasites, while for a
drug with a short half-life, such as AL or ACT, this time period is about 6 days [18]. These are the
same values used in [28]. For the number of IPT treatments given per person per day, c, we use the
value 0.016 day−1 as in [23, 28]. This value corresponds to IPT being given once every 60 days, or
1/c. Since a goal of this manuscript is to see the impact of IPT in averting disease induced deaths,
we will vary c to see the role frequency of IPT administration might have on the number of child
disease-induced mortality and the rate of resistance spread.
The average number of days needed to clear an infection with appropriate treatment is 1/a.
Assuming that treatment is pursued immediately, and a WHO recommended dosage is taken within
the required dosage time frame, then 1/a is about 5 days [23]. If the strain of malaria is not fully
responsive to the drug, then pa measures the rate of clearing an infection via treatment where
0 ≤ p < 1. If p = 0 then the malaria strain is fully resistant to the drug and treatment is ineffective.
For values of 0 < p ≤ 1, the resistant strain of malaria partially responds to treatment. We also
assumed that asymptomatic and symptomatic infections of mature individuals are naturally cleared
at the same rate (σma = σms), as in [23], where a value of 1/33 days
−1 was used. Mean rates of
immune-response related clearance of 1/180 days−1 have also been cited in [12]. Here, we chose a
baseline value based on a weighted average.
Our focus was on regions were malaria is holoendemic. These regions could either have low or
high malaria transmission intensity. Low transmission intensity areas are typically upland sites (see,
e.g. [8]) and tend to exhibit conditions that make them less conducive for the malaria transmitting
mosquito to reproduce [25]. Such conditions may include lower rainfall accumulations and cooler
temperatures due to the altitude. Thus, with fewer mosquitoes, there are less contacts, on average,
between humans and infectious female mosquitoes [23, 25]. On the other hand, high transmission
regions, typically at lower elevations [8], have conditions that enhance the breeding and hence growth
and reproduction of the female mosquito population. Thus, in high transmission regions, there is
a higher on average contact between humans and infectious female mosquitoes [23, 25]. We used
estimates from Chitnis et al. [5] to inform our high and low mosquito biting, vector-to-host ratio,
and transmission parameters.
Malaria mortality rates have been monitored since 2001 by Kenya Medical Research Institute
(KEMRI) and the U.S. Centers for Disease Control and Prevention (CDC) as part of the KEMRI/CDC
Health and Demographic Surveillance System (HDSS) in rural western Kenya [11]. The results
published in [11] show a declining malaria disease-induced mortality rate in all age groups, with
the 2010 data reported as 3.7 deaths per 1000 person-years for children under five, with a 95%
confidence interval reported to be between 3.0 and 4.5 per 1000 person-years. For individuals five
and above, the malaria mortalities were estimated for 2010 as 0.4 deaths per 1000 person-years,
with a 95% confidence interval reported to be between 0.3 and 0.6 per 1000 person-years. The study
appears to have accumulated the deaths yearly during the time frame used. The area of the study,
around where KEMRI/CDC HDSS is located, is in the lake region of western Kenya, a malaria
endemic region considered to be of high transmission intensity [11]. For disease mortality in regions
of low transmission intensity, we assume a 3.5 times reduction in the under five malaria-related
mortality. This assumption comes from the findings in [24] that reported an approximately 3.5 times
overall malaria-specific mortality in children in areas of higher stable transmission than in areas of
low malaria transmission intensity in Sub-Saharan Africa, excluding southern Africa.
To initialize our simulations, we used a human density (in a 500 km2 region of the KEMRI/CDC
HDSS area the population density is 135,000 per km2) and estimated mosquito density to be 3 times
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the human density for high transmission regions and 1 time the human density for low transmission
regions [1]. We assumed that both human and mosquito populations are constant in the absence of
the disease, which implies equal birth and death rates for each species. Using the data in Table 4, we
computed the human birth rate to be Λh =
(#births per 1000 people per year)
1000 people × 1 year365 days ×N∗h where N∗h
is the total human population. To keep the total population constant (apart from malaria deaths),
the juvenile natural death rate was computed to be µh =
Λh
N∗c
− η where N∗c is the total number
of juveniles. Then, the mature death rate is µmh =
ψη
1−ψ where ψ = N
∗
c /N
∗
h is the fraction of the
population in the juvenile class.
The natural mosquito death rate, µv, is assumed to be the reciprocal of the average lifetime of a
mosquito. In the wild, mosquitoes are thought to live for about two weeks, though other modeling
efforts have used values ranging up to 28 days [22, 26, 27]. We set the mosquito emergence rate to
be Λm = µvQNh, where Q is the number of mosquitoes per human. We assume the mosquito biting
rate range to be α ∈ (0.2, 0.5) per day [19].
3 Model Analysis
In this section, we derived the stability conditions of the disease-free equilibrium. We computed the
basic reproduction number for the resistant and sensitive strains and present biological interpretations
of the expressions. We also derived the invasion reproduction numbers and present invasion maps
for the resistant and sensitive strains of malaria.
3.1 The disease-free equilibrium (DFE)
Let X = (Is, Ia, Js, Ja, Ims, Ima, Jms, Jma,Ms,Mr, S, Ts, T, Ta, R, Sm, Tms, Tm, Tma, Rm, Sv) denote
an equilibrium of the system described by equations (1b)-(1j), (2b)-(2j) and (4a)-(4c). The system
has the DFE E0 = (0, 0, 0, 0, 0, 0, 0, 0, 0, 0, S0, 0, T0, 0, Sm0, 0, Tm0, 0, Sv0), where
S0 =
Λh (r + µh + η)
(µh + c+ η) (r + µh + η)− rc , T0 =
c
r + µh + η
S0
(6a)
Sm0 =
η
µmh
(
1 +
rc
(µmh + r) (r + µh + η)
)
S0, Tm0 =
ηc
(µmh + r) (r + µh + η)
S0, Sv0 =
Λv
µv
.
Table 4: Data from [4] on the three African countries, Kenya Ghana and Tanzania, used to determine
current natural death rates and to infer death rates for malaria in our model.
Data Information Kenya Ghana Tanzania
Total Population 45,925,301 26,327,649 51,045,882
< 5 years old in millions ≈ 3.3 ≈ 1.9 ≈ 4.1
Infant mortality: deaths/1,000 live births) 39.38 37.37 42.43
Births/1,000 population 26.4 31.09 36.39
Deaths/1,000 population 6.89 7.22 8
Life expectancy at birth in years 63.77 66.18 61.71
Calculated proportion under 5 0.0719 0.0722 0.0804
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Table 5: Parameter values, ranges, and references that are unchanged across high/low transmission
scenarios.
Parameter Value Range Baseline Value Reference
Λh (2.24× 103, 5.08× 103) 3.55× 103 CIA data
µh (4.583× 10−4, 6.922× 10−4) 5.94× 10−4 CIA data
µmh (4.25× 10−5, 4.791× 10−5) 4.43× 10−5 CIA data
µv (1/7, 1/21) day
−1 1/14 day−1 [27]
δm
(
0.3
1000∗365 ,
0.6
1000∗365
)
day−1 0.41000∗365 day
−1 [11]
δ
(
3.0
1000∗365 ,
4.5
1000∗365
)
day−1 3.71000∗365 day
−1 [11]
1/ω (28) 28 day [23]
1/ω′ (370) 370 day [23]
ν (0.001, 0.05) 0.01 [23]
ν′ (0.001, 0.05) 0.05 [23]
σms (1/28-1/365) 1/33 day
−1 [12, 23]
σma (1/28-1/365) 0.03 day
−1 [12, 23]
1/a (3,10) 5 days [23]
c (0.005,0.03) 0.016 day−1 [23]
1/r, 1/rs constant 1/6, 1/52 day
−1 [23]
Table 6: Parameter values, ranges, and references that change across high/low transmission scenarios.
Parameter Value Range High Baseline Value Low Baseline Value Reference
Λv (1− 10) ∗Nh/µv 3 ∗Nh/µv 1 ∗Nh/µv [1, 5]
βv (0.03,0.2) 0.0927 0.0313 [5]
βh (0.18,0.9) 0.5561 0.1251 [5]
κv (0,1) 0.6 0.6 assumed
κh (0,1) 0.6 0.6 assumed
σa (1/365-1/20) 1/33 day
−1 1/180 day−1 [12, 23]
σs (0.02-0.05) 0.03 day
−1 1/365−1 [12, 23]
p (0,1) 0.3 0.1 assumed
λ (0.25,0.75) 0.5 0.7 [23]
λ′ (0.15,0.35) 0.2 0.7 [3, 23, 25]
ξm (0.8,1) 0.9 0.5 [3, 23, 25]
ξ (0.1,0.5) 0.4 0.2 [3, 23, 25]
b (0.25,0.50) 0.5 0.25 [23]
bm (0.25,0.50) 0.5 0.25 [3, 23, 25]
δ 1.0137e-05 2.8963e-06 [11]
1/η 5 yrs 8 yrs [3]
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3.2 Basic reproductive numbers
The basic reproduction numbers for the sensitive parasite strain Rs and the resistant parasite strain
Rr were computed using the next generation matrix, as well as derived from biological interpretation
of the model. Details of both approaches are listed in Appendix B. The reproduction number for
the sensitive strain of infection takes the following form:
R2s =
βvβhS0Sv0
µvN20
[
1− λ
Aa
+
ν(1− λ)
AaAs
+
ην(1− λ)
AaAmsAs
+
η(1− λ)
AaAma
+
ην′(1− λ)
AaAmaAms
+
λ
As
+
ηλ
AsAms
]
+
βvβhSm0Sv0
µvN20
[
1− λ′
Ama
+
ν′(1− λ′)
AmaAms
+
ν′
Ams
]
.
(7)
The reproduction number for the resistant strain of infection takes the following form:
R2r =
κvβvκhβh(S0 + T0)Sv0
µvN20
[
1− λ
Ba
+
ν(1− λ)
BaBs
+
ην(1− λ)
BaBmsBs
+
η(1− λ)
BaAma
+
ην′(1− λ)
BaAmaBms
+
λ
Bs
+
ηλ
BsBms
]
+
κvβvκhβh(Sm0 + Tm0)Sv0
µvN20
[
1− λ′
Ama
+
ν′(1− λ′)
AmaBms
+
ν′
Bms
]
.
(8)
Where, the following parameters represent the durations of infections:
As = a+ µh + η + δ ⇒ 1
As
= duration of sensitive sym. naive infection
Aa = c+ ν + σa + µh + η ⇒ 1
Aa
= duration of sensitive asym. naive infection
Ams = a+ µmh + δm + σms ⇒ 1
Ams
= duration of sensitive sym. mature infection
Ama = ν
′ + σma + µmh ⇒ 1
Ama
= duration of sensitive asym. mature infection
Bs = pa+ µh + η + δ ⇒ 1
Bs
= duration of resistant sym. naive infection
Ba = ν + σa + µh + η ⇒ 1
Ba
= duration of resistant asym. naive infection
Bms = pa+ µmh + δm + σms ⇒ 1
Bms
= duration of resistant sym. mature infection
(9)
Note that for a mature individual, the duration of a resistant asymptomatic infection is equivalent
to the duration of a resistant symptomatic infection (1/Ama).
The reproductive numbers depend on the IPT treatment regime and drug efficacy (Figure 4).
The rate of IPT administration to individuals per day (c) has a small influence on Rs (Figure 4
b, d). The drug efficacy (p) influences Rr (Figure 4 a, c). For both low and high transmission
scenarios, Rr decreases for increasing levels of p. While increasing p decreases Rr, it is unable to
bring Rr < 1 in the high transmission scenario (Figure 4 c).
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(a) (b)
(c) (d)
Figure 4: Reproduction numbers for the low transmission scenario (top graphs (a) and (b)) and
high transmission scenario (bottom graphs (c) and (d)) for varying values of p and c. All other
parameter values are given in Tables 5 and 6. Notice the different scales on the y-axes. In the low
transmission region, R0 is rarely above 1.
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Table 7: Reproduction and invasion numbers for the low and high transmission scenarios using
baseline parameter values from Tables 5 and 6. Since the low transmission basic reproduction
numbers are less than one (so no sensitive- or resistant-only equilibria exist), we do not compute the
invasion reproductive numbers.
Low Transmission High Transmission
Rs Rr Rs Rr Rrs Rsr
rs = 1/6 0.8148 0.5811 4.5217 2.9984 1.329 4.533
rs = 1/52 0.8148 0.5811 4.5217 2.9984 1.0821 6.7323
Table 7, presents the reproductive numbers for the sensitive strain, Rs, and resistant strain, Rr,
using baseline parameter values for the low and high transmission scenarios in equations (7) and (8).
In the low transmission scenario both Rs and Rr are less than unity and malaria only persists in
low transmission regions with regular introductions from outside. In the high transmission scenario
both Rs and Rr are greater than unity and malaria persists.
3.3 Invasion Reproduction Numbers
The basic reproduction number is not sufficient to determine the competitive outcome of the resistant
and sensitive strains. In addition to Rs and Rr, we must derive the invasion reproduction numbers
Rsr and R
r
s, which are threshold quantities determining whether the resistant strain is able to
invade the sensitive-strain boundary equilibrium, and vice versa. The derivation follows the Next
Generation Approach, but with the disease-free equilibrium replaced with either the sensitive-only
boundary equilibrium, or the resistant-only boundary equilibrium.
The square of the thresholds determining whether the resistant strain can invade the sensitive-
only boundary equilibrium, and whether the sensitive strain can invade the resistant-only boundary
equilibrium is given by:
(Rsr)
2 =
βvkvS
∗
v
µvN∗h
· βhkh
N∗h
{
(S∗m + T
∗
m + T
∗
ma + T
∗
ms)
[
(1− λ′)
Ama
+
λ′
Bms
+
(1− λ′)ν′
AmaBms
]
+(S∗ + T ∗a + T
∗
s + T
∗)
[
1− λ
Ba
+
η(1− λ)
AmaBa
+
λ
Bs
+
ηλ
BmsBs
+
(1− λ)ν
BaBs
+
η(1− λ)(Amaν +Bsν′)
AmaBaBmsBs
]}
(Rrs)
2 =
βhβvS
∗
v
µv(N∗h)2
{
S∗m
[
λ′
Ams
+ (1− λ′)
(
1
Ama
+
ν′
AmsAma
)]
+S∗
[
λ
(
1
Ams
+
η
AsAms
)
+ (1− λ)
(
1
Aa
+
η
AaAma
+
ν
AsAa
+
η(Amaν +Asν
′)
AsAaAmsAma
)]}
,
(10)
where the equilibrium values correspond to the sensitive-only, and resistant-only boundary equilibria,
respectively. Table 7 presents the invasion reproductive numbers (Rrs, Rsr) using baseline parameter
values for the low and high transmission scenarios in equation (10). Here the variables notes with ∗
are at equilibrium for their respective strain-only equilibria.
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4 Numerical Results
In this section, we present results from numerical simulations for the high and low transmission
regions. Our quantities of interest (QOI), or outputs, were number of children who died of malaria,
number of adults who died of malaria, and the proportion of deaths that resulted from infection with
the resistant strain. For both regions we consider two IPT/treatment regimes: (1) SP/SP where
SP, a long half-life drug (and could be replaced with another similar long half-life drug) is used for
both IPT and treatment, and (2) SP/ACT where SP (the long half-life drug) is used for IPT and
ACT, a short half-life drug (and could also be replaced by another similar short half-life drug such
as AL), is used for treatment of symptomatic infection. We denote these scenarios as long/long
and long/short. We also compute PRCC sensitivity indices for our outcomes to the parameters
used. For simplification, and in an abundance of caution, we assume that the IPT drug and dose
given is completely ineffective against the resistant pathogen when given to asymptomatic juveniles.
The drug and dosages used for symptomatic treatment of the resistant pathogen, however, may be
partially effective depending on the value chosen for p.
4.1 Numerical Results: High Transmission Region
For the following figures we assume a high transmission region with an initial population of
N = 35, 000, 000 humans and a constant population of 105, 000, 000 mosquitoes. Initial conditions:
Nchild = 7.5%N , S(0) = Nchild, Ia(0) = Is(0) = Ja(0) = Js(0) = T (0) = Ta(0) = Ts(0) = R(0) = 0.
For the adults, Nadult = 92.5%N , Sm(0) = 53%Nadult, Ima(0) = 10%Nadult, Ims(0) = 5%Nadult,
Jma(0) = Jms(0) = 1%Nadult, Rm(0) = 30%Nadult, with all other classes equal to zero. For the
mosquitoes, we assume Sv(0) = 90%Nmosquito, Mr(0) = Ms(0) = 5%Nmosquito.
Figure 5(a) shows the total changes in number of child deaths due to IPT for various values of p in
the high transmission region using drugs with long half-life for both IPT and treatment (long/long).
For p = 0.3, some lives are saved over the course of 1 year, but by 5 or 10 years, IPT increases
resistance enough that there is a net increase in number of deaths. In order to see a net number
of lives saved over 10 years, p must be greater than or equal to 0.4. Figure 5(b) shows the total
changes in number of child deaths due to IPT for various values of p in the high transmission region
using a drug with long half-life for IPT and a drug with short half-life for treatment (long/short).
Here we always see a net increase of number of lives save regardless of the value of p.
Figure 6 shows the effects of IPT on the number of sensitive strain malaria deaths averted under
the long/long scenario. It illustrates how the use of IPT reduces number of sensitive deaths but can
in fact increase number of deaths from resistant infections for mid-range values of p. For very low
values of p in the high transmission region, the resistant strain becomes dominant quickly, so IPT
has very little impact on anything. Since we assume that the resistant strain has some kind natural
competitive disadvantage compared to the sensitive strain, symptomatic treatment is driving this
take over. The number of deaths from resistant infections is significantly reduced for p ≥ 0.4. High
values of p decrease the total number of malaria deaths by diminishing the duration of the resistant
symptomatic infection. This is seen in the expressions for Bs and Bms in equation (9).
Figure 7 shows the impact IPT has on the percent of cases that are resistant for a fixed value of p.
In Figure 7(a), we see that for p = 0.3 (which is right on the border of resistance really dominating),
the percent of cases that are resistant will increase steadily over the course of 10 years without IPT.
However, the use of IPT (Figure 7(b)) will drive the proportion of resistant cases higher, particularly
in children. Thus, IPT usage can work synergistically with treatment to allow resistant strains to
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(a) SP Treatment (b) AL Treatment
Figure 5: High transmission region: Net increase in deaths due to IPT usage, or (Total child deaths
due to sensitive and resistant strains of malaria with IPT) - (total child deaths without IPT) for 1
year, 5 years, and 10 years of IPT use for different levels of standard treatment effectiveness against
the resistant strain, p. (a) is for long half-life SP used as the treatment drug and (b) is for short
half-life AL used for symptomatic treatment. Negative numbers indicate lives saved due to IPT
while positive numbers indicate more deaths from using IPT.
increase and take over. However, for p > 0.3, this effect is muted.
Figures 8 and 9 investigate how different rates of IPT treatments and treatment drug half-life
influence the dynamics after 10 years. Figure 8 shows that in the high transmission region with
long/long drug half-lives and p = 0.3, increases in time between IPT treatments, 1/c reduces the
effects of malaria. In this scenario the model predicts that the use of IPT has negative consequences,
as the number of infections, children death, and percentage of resistant cases is high for low values
of 1/c. Figure 9(a) shows that in the same scenario but with p = 0.5, the use of IPT is beneficial.
Here increasing time between IPT treatments, 1/c, increases the number of infections and children
deaths. In high transmission regions using long/long drug half-lives, we see that IPT should only be
used for high values of p. Figures 8(c)-(d) and 9(b) show that in the high transmission region with
long/short drug half-lives, IPT is beneficial in reducing the number of infections and child deaths.
However, when p = 0.3 although the total number of infections is low for low values of 1/c, the
percentage of resistant infections is high (Figure 8(c)-(d)).
We see in Table 8 that the total number of deaths of children from malaria increases dramatically
as the value of p decreases for long/long drug half-lives. So, as strains develop more resistance to
the drug used for treatment (low values of p), the number of deaths will increase if no new effective
drug is available or put into use. For example, in the high transmission region, for p = 0.1, there are
nearly 10 times the number of deaths as for p = 0.5. For high transmission regions, this effect is
much more pronounced and occurs for higher values of p. For high transmission, number of deaths
start drastically increasing for p < 0.3, but for low transmission, this occurs for p < 0.11. We can
also see that IPT only results in significant (> 10%) reductions in total number of children deaths
for p > 0.4 and over 10 years in the high transmission region. For low transmission, if p > 0.11, then
a > 10% reduction in child deaths occurs over 5 or more years. It is also interesting to note the
distinctly non-linear relationship between p and number of lives saved/lost due to IPT.
Finally, Figures 10 and 11 illustrate how differences in IPT and treatment half-lives can change
results in the high transmission region. In Figure 10, the top row shows the relationship between
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(a) Sensitive Infections (b) Resistant Infections
Figure 6: High transmission region, SP for treatment: Change in child malaria deaths by use of
IPT separated by infection type, treatment level for the resistant infection, and number of years
since beginning of IPT treatment. Subfigure (a) is child sensitive infection deaths averted (sensitive
deaths in a scenario without IPT minus sensitive deaths in the same scenario with IPT). Subfigure
(b) is the additional number of child deaths due to resistant infection with IPT usage. IPT treatment
can reduce the number of child deaths due to the sensitive infection, but increase the number of
child deaths due to the resistant strain for some scenarios. Notice the different scales on subfigures
(a) and (b).
IPT treatment frequency, c, and resistance strength, p, with number of deaths from the resistant
strain of malaria at the endemic equilibrium for long/short half-lives. The left figure is for a wide
range (with some unrealistically high application rates) of IPT, while the right figure looks at more
realistic values of c < 0.1 corresponding to IPT treatment schedules of greater than 10 days. The
total number of deaths from the resistant strain is almost exclusively dependent on the value of
p, with some slight change as c increases for the long/short IPT/treatment half-lives. The bottom
row is the same scenario except for long/long IPT/treatment half-lives. In this case, c has no
discernible effect. This figure also shows the extremely wide range of total number of child and adult
deaths as resistance levels increase, or values of p decrease. It also illustrates that the long/short
scenarios requires lower values of p to result in higher numbers of deaths than the long/long scenario.
Figure 11, showing dependence of proportion of deaths that are resistant on c and p, highlights the
difference between long/short (top row) and long/long (bottom row) regimes. We see that if both
IPT and treatment have long half-lives (bottom row), then the space where the resistant strain
dominates is much larger. When IPT is long half-life but treatment is short half-life (top row) there
is a wide range of parameter space for which the proportion resistant is low. It is also important to
note that for this high transmission region, use of IPT affects proportion of deaths from the resistant
strain in both adults and children. This implies that IPT is directly changing the dynamics of the
resistant strain.
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(a) No IPT (b) With IPT
Figure 7: High transmission region, SP for treatment (long/long scenario), p = 0.3: Proportion of
cases that are resistant over ten years. We ran the model with initially low levels of resistance and
no IPT for 10 years, then begin IPT usage and track next ten years. There are no figures when AL
is used for treatment (long/short case) because the resistant strain dies out for this scenario.
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(a) SP Ratio Resistant (b) SP Total Child Deaths
(c) AL Ratio Resistant (d) AL Total Child Deaths
Figure 8: High transmission region, p = 0.1: Ratio of resistant infections to total infections (left)
and total child deaths (right) after 10 years of IPT for varying time between IPT treatments, 1/c,
and for various values of r−1, the time chemoprophylaxis lasts in susceptible IPT treated humans.
(Top Row: (long/long) scenario) Symptomatic treatment is SP. (Bottom Row: (long/short
scenario)) Symptomatic treatment is AL. Initial conditions are the same as in Figure 7. For both
AL and SP symptomatic treatment, any IPT will result in more resistance and more deaths for
p = 0.1. When the short half-life AL drug, the level of resistance and number of deaths is less than
when SP is used for symptomatic treatment (long/long).
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(a) SP Total Child Deaths (b) AL Total Child Deaths
Figure 9: High transmission region, p = 0.5: Total child deaths after 10 years of IPT for varying
time between IPT treatments, 1/c, and for various values of r−1, the time chemoprophylaxis lasts
in susceptible IPT treated humans. (Left: long/long scenario) Symptomatic treatment is SP.
(Right: long/short scenario) Symptomatic treatment is AL. Initial conditions are the same as
in Figure 7. In this case, both SP and AL scenarios with IPT result in lives saved. However, since
resistance is low, using SP for symptomatic treatment is the best choice (saves more total lives).
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Figure 10: Heatmap of the number of deaths from the resistant strain for the high transmission
region. (Top Row: (long/short) scenario) AL for symptomatic treatment and (Bottom
Row:(long/long) scenario) SP for symptomatic treatment. The right column is a zoom-in of the
left column to show more realistic values of c, the rate at which IPT is given. The parameter p is
the effectiveness of the treatment drug on the resistant strain, so p = 0 is fully resistant and p = 1 is
fully sensitive. Number of deaths is dependent almost exclusively on p.
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Figure 11: Heatmap of the proportion of deaths from the resistant strain for the high transmission
region and for (Top Row: (long/short) scenario) AL for symptomatic treatment and (Bottom
Row: (long/long) scenario) SP for symptomatic treatment. The right column is a zoom-in of
the left column to show more realistic values of c, the rate at which IPT is given. Note different
scales for top and bottom rows. The proportion of deaths from the resistant strain is dependent on
both p and c, showing that IPT schedule can increase resistance.
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4.2 Numerical Results: Low Transmission Region
For the low transmission region we changed the parameters to match the low transmission parameters
in Tables 5 and 6. For this scenario, the total number of child deaths from malaria are at least an
order of magnitude smaller than in the high transmission region (see Table 8). In sheer numbers, then,
IPT and treatment will have a lower impact in the low transmission region. The basic reproduction
numbers for the sensitive and resistant strains are less than one at our low transmission baseline
parameters, Table 7. Figure 4 (top left) shows that for very low values of p, indicating very high
resistance to the treatment drug, the resistant strain has R0 > 1, greater than the sensitive strain
reproduction number. In Figure 4 (top right), the sensitive strain reproduction number is slightly
reduced by c at very low values of c, corresponding to very infrequent IPT, but remains unchanged
after that. The resistant reproduction number is unchanged by c. This means that frequency of IPT
application has very little impact on either reproduction number for the low transmission region.
In Figure 12(a), for p > 0.11, IPT results in a net gain of lives saved for 1 year, 5 years, and 10
years for the long half-life drug SP used as treatment and as IPT. Past that point, in fact, there
is very little difference across all values of p, unlike the high transmission scenario. However, as
expected, the number of lives saved is an order of magnitude less than for the high transmission
region, Figure 5. For p < 0.11, application of IPT results in an increase in deaths over 5 and 10
years. There is a bifurcation point for p where the dominant strain switches from the sensitive
to the resistant strain. Once the resistant strain is dominant, widespread use of the drug that it
is resistant to leads to more rather than fewer deaths. When the short half-life drug AL is used
for treatment and SP for IPT, Figure 12(b), we see a very similar bifurcation point at p = 0.11
below which the resistant strain takes over and spreads, resulting in IPT being not only ineffective,
but damaging. It is interesting to note that the increase in number of deaths from using IPT at
p = 0.10 for AL treatment is double the increase in deaths from IPT when SP is used for treatment.
This is in contrast to the high transmission region where using SP as treatment results in a higher
increase in deaths resulting from IPT usage (Figures 5(a) and (b)). However, it should be noted
that although the increase in deaths from using IPT is larger for AL treatment, the total number of
deaths is larger when SP is used for both treatment and IPT, Table 8.
In Table 8, we see that the resistant strain only dominates after introduction in the low
transmission region for very low values of p, which equates to very high resistance to the drug
used for treatment in the resistant strain. For the long/long IPT/treatment half-life scenario,
the total number of deaths jumps by more than a factor of 3 when p = 0.09. For the long/short
scenario, a smaller jump in cases is seen at p = 0.09. In absolute numbers, IPT saves more lives
in the high transmission region, but as a percent reduction of total deaths, IPT does better in the
low transmission region. Another interesting pattern is that for higher values of p, using short
half-life treatment results in more deaths than using long half-life treatment. However, once a highly
resistant strain is circulating, the long/short regime has lower total deaths than long/long. For
example, in the low transmission region, when p = 0.10, there are 1,599 deaths without IPT and
1,836 deaths with IPT for long/long after 5 years. By contrast, for long/short there were 698 deaths
without IPT and 1,060 deaths with IPT. If a very resistant strain is circulating it is better to use a
short half-life treatment drug.
At the inflection point p = 0.11, Figure 13(a) shows that the proportion of cases resistant stays
at a low and constant level over 10 years. However, when IPT is applied, it will slowly increase
the proportion of resistant cases for children and adults after 10 years, Figure 13(b). In this case,
since IPT is applied only to children, the proportion of resistant cases is in children is roughly
double that in adults after 10 years. In Figure 14(a), with short half-life AL used for treatment,
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the resistant strain decreases to zero with time rather than staying steady. Secondly, in Figure
14(b), the proportion resistant does increase with the use of IPT, but at a very slow rate compared
to the high transmission region (notice the difference in scales). In general, with a strain that
is very resistant to the treatment, it is better to employ the short half-life drug and not to use
IPT in the low transmission region to control the spread of resistance. In fact, at p = 0.11, lower
levels of resistance are always obtained by using an IPT drug with the shortest half-life and at very
infrequent intervals, Figure 15. Again, the short half-life drug used for treatment results in an order
of magnitude lower level of resistance than the long half-life drug.
(a) SP Treatment (b) AL Treatment
Figure 12: Low transmission region: Net increase in deaths due to IPT usage, or (Total child deaths
due to sensitive and resistant strains of malaria with IPT) - (total child deaths without IPT) for
1 year, 5 years, and 10 years of IPT use for different levels of standard treatment effectiveness
against the resistant strain, p. (a) SP used as the symptomatic treatment drug and (b) AL used for
symptomatic treatment. Negative numbers indicate lives saved due to IPT while positive numbers
indicate more deaths from using IPT.
(a) No IPT (b) With IPT
Figure 13: Low transmission region, SP for symptomatic treatment, p = 0.11. Proportion of
infections that are resistant (ratio of resistant strains of infection to the sum of resistant and sensitive
infections) over ten years.
When the treatment used is still partially effective against the resistant strain (p = 0.3), then
applying IPT more frequently and for longer half-live drugs will lead to lower total number of
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(a) No IPT (b) With IPT
Figure 14: Low transmission region, AL for symptomatic treatment, p = 0.11. Proportion of
infections that are resistant (ratio of resistant strains of infection to the sum of resistant and sensitive
infections) over ten years. Notice that the scale here is 1/10 of that in Figure 13.
infections and childhood deaths, Figure 17. However, when the treatment drugs are very ineffective
against the resistant strain (p = 0.1) then longer time between IPT application and a shorter IPT
drug half-life always leads to a decrease in resistance, infections, and deaths, Figure 16. There are
similar patterns for this behavior when a short half-life treatment drug, AL, is used, Figures 16(b)
and 17(b). In short, there is a sharp regime change above which frequent IPT and long-half life
drugs are useful but below which they can be deleterious.
Next we present heatmaps of number of child deaths from malaria across p and c space for
the low transmission region for long/short (Figure 18, left) and for long/long (Figure 18, right)
IPT/treatment half-lives. For both scenarios, the number of deaths depends almost exclusively on
the value of p, or resistance to the treatment drug. However, the proportion of deaths from the
resistant strain, Figure 19, does depend on c, or the frequency of IPT application, particularly as
values of p increase. Also, unlike the high transmission region, the number of deaths from malaria
in adults is unchanged by IPT usage.
Figure 20 gives more information about why we see some distinct impacts on levels of resistance
and number of deaths as p varies for the high and low transmission regions. For the high transmission
region (Figure 20(a)), resistance dominates to the exclusion of the sensitive strain for p < 0.1
(long/long). For approximately 0.1 < p < 0.4, the fraction of sensitive increases with p while
fraction resistant decreases but both strains coexist. Finally, for p > 0.4, the sensitive strain is
dominant to the exclusion of the resistant strain and the sensitive strain persists at endemic but
relatively low levels due to treatment. For the low transmission region (Figure 20(b)), the resistant
strain dominates until about p = 0.1, at which point it drops precipitously while the sensitive
strain increases for 0.1 < p < 0.2 after which the resistant strain is extinct and the sensitive strain
persists at low and steady levels due to treatment. The scales are again different for high and low
transmission regions, which reflects the much higher prevalence of malaria in the high transmission
regions.
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Table 8: Total number of child deaths from malaria for various values of p and either no IPT or
IPT used. The (IPT/treatment) half-lives are also noted where the long half-life drug is SP and the
short half-life drug is (AL). For high resistance to treatment (low values of p), the total number of
deaths is much higher than for lower resistance to treatment. The cut-off for this dramatic increase
in number of deaths is at about p = 0.3 for the high transmission region and about p = 0.1 for the
low transmission region for long/long scenario.
Year 1 Year 5 Year 10
p No IPT IPT No IPT IPT No IPT IPT
High transmission region, long/long
0.1 77,743 77,823 118,505 119,455 171,716 174,047
0.2 26,806 27,103 43,929 46,795 67,258 73,304
0.25 14,860 14,973 25,622 28,221 40,901 46,687
0.3 9,158 9,052 14,772 16,771 24,720 29,759
0.35 8,533 8,407 12,167 11,375 16,959 18,864
0.4 8,394 8,141 12,021 10,990 16,717 14,742
0.5 8,254 8,052 11,878 10,888 16,575 14,605
Low transmission region, long/long
0.09 2,309 2,308 4,950 4,961 9,179 9,192
0.1 696 684 1,599 1,836 4,125 4,930
0.11 323 303 503 379 787 497
0.12 313 295 495 373 784 503
0.13 300 281 482 359 772 490
0.15 301 285 484 363 774 494
0.2 288 270 471 348 760 479
0.3 279 268 462 346 751 477
High transmission region, long/short
0.1 13,500 13,147 19,596 17,080 27,522 22,776
0.2 13,341 12,955 19,440 16,714 27,367 22,292
0.25 13,275 12,842 19,371 17,134 27,318 22,822
0.3 13,235 12,572 19,331 16,847 27,258 22,425
0.35 13,208 12,649 19,304 16,762 27,230 22,508
0.4 13,187 12,856 19,284 16,784 27,212 22,424
0.5 13,164 12,793 19,260 17,068 27,187 22,678
Low transmission region, long/short
0.09 1,539 1,536 3,741 3,866 7,688 7,877
0.10 499 765 698 1,060 1,137 2,658
0.11 380 366 650 459 940 622
0.12 358 340 572 428 915 577
0.13 349 326 563 415 906 563
0.15 340 323 554 411 896 559
0.2 329 316 543 404 886 552
0.3 321 300 535 388 878 537
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(a) SP treatment (b) AL treatment
Figure 15: Low transmission region, p = 0.11: Ratio of resistant infections to total infections (left)
and total child deaths (right) after 10 years of IPT for varying time between IPT treatments, 1/c,
and for various values of r−1, the time chemoprophylaxis lasts in susceptible IPT treated humans.
(a) is SP symptomatic treatment and (b) is AL symptomatic treatment. Note that the y-axis in (a)
is 10 times that in (b).
(a) SP Number Child Deaths (b) AL Number Child Deaths
Figure 16: Low transmission region, p = 0.1: Total child deaths after 10 years of IPT for varying
time between IPT treatments, 1/c, and for various values of r−1, the time chemoprophylaxis lasts
in susceptible IPT treated humans. (Left) is for SP used for symptomatic treatment, (Right) is
AL used for symptomatic treatment. Initial conditions are the same as in Figure 7. In this case,
both SP and AL scenarios with IPT result in an increase in deaths due to the circulation of a highly
resistant strain.
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(a) SP Total Child Deaths (b) AL Total Child Deaths
Figure 17: Low transmission region, p = 0.3: Total child deaths after 10 years of IPT for varying
time between IPT treatments, 1/c, and for various values of r−1, the time chemoprophylaxis lasts
in susceptible IPT treated humans. (Left) is for SP used for symptomatic treatment, (Right) is
AL used for symptomatic treatment. Initial conditions are the same as in Figure 7. In this case,
both SP and AL scenarios with IPT result in saved lives.
Figure 18: Heatmap of the number of deaths from the resistant strain for the low transmission
region. (Left: (long/short) AL for treatment and (Right: long/long) SP for treatment. The
parameter p is the effectiveness of the treatment drug on the resistant strain, so p = 0 is fully
resistant and p = 1 is fully sensitive. Number of deaths is dependent almost exclusively on p and is
much lower than the high transmission region. The zoom for realistic values of c looks very similar
to the shown figures, so is omitted.
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Figure 19: Heatmap of the proportion of deaths from the resistant strain for the low transmission
region and for (Top Row: long/short) AL for treatment and (Bottom Row: long/long) SP
for treatment. The right column is a zoom-in of the left column to show more realistic values of
c, the rate at which IPT is given. Note different scales for top and bottom rows. The proportion
of deaths from the resistant strain is dependent on both p and c, showing that IPT schedule can
increase resistance. However, unlike for high transmission, in this case the adult population is not
affected by IPT.
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(a) High Transmission Region (SP) (b) Low Transmission Region (SP)
(c) High Transmission Region (AL) (d) Low Transmission Region (AL)
Figure 20: Fraction of the total population infected with sensitive and resistant strains at t=10
years when both treatment and IPT are applied the whole time. Note that the region for coexistence
of the sensitive and resistant strains has a small range. As p increases, more people with the
symptomatic resistant strain get effective treatment, thereby shortening the infectious period. The
scale for each y-axis is different.
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5 Parameter Sensitivity
Latin hypercube sampling (LHS) [21], is a technique that uses stratified sampling without replacement.
The LHS technique takes np parameter distributions, divides them into N predetermined equally
probable intervals, and then draws a sample from each interval. For the system described by
equations (1b)-(1j), (2b)-(2j) and (4a)-(4c), with np = 18 parameters, the technique generates a
hypercube of size N , chosen to be 5000 row by 18 column matrix of parameter values. Each set of
18 parameter values is then used to generate a solution for the system given in equations (1b)-(1j),
(2b)-(2j) and (4a)-(4c) for a total of 5000 simulations. The LHS method performs an unbiased
estimate of the average model output, sampling each parameter interval shown as ranges in Tables 5
and 6 exactly once.
Figures 21 and 22 show only the statistically significant parameters (p-test value < 0.01). Note
that as time increases from 1 year to 5 years to 10 years since the start of IPT, the significance of p
decreases for the sensitive and resistant infections. This is expected as the reproduction numbers RS
and RR do not depend on p. However, the PRCC plot illustrates that the number of child deaths
due to the resistant strain greatly decreases as p increases. This is a result we have seen repeatedly
in our numerical simulations, illustrating that numerical simulations add to our understanding of
the dynamical progression of IPT and its influence on death prevention and disease resistance. The
PRCC plots for the high and low transmission regions show the same sensitivities as we have the
same model for both regions with only changes in parameter values.
(a) Child, 1 Year (b) Child, 5 Years
Figure 21: Note that as time increases, the sensitivity to p decreases for infections, but not for
deaths. Each parameter has a quartet of bars representing the PRCC values for sensitive child
infections, resistant child infections, sensitive child deaths, and resistant child deaths.
We can see in Figures 21 and 22 that, for all QOI, µv and σa, the death rate of mosquitoes
and rate at which asymptomatic juveniles clear infection naturally, are extremely important. As
the lifespan of the mosquito decreases (or µv increases), the QOI all decrease. As the time spent
asymptomatic but still infectious for juveniles decreases (so σa increases), the QOI all decrease.
Additional important parameters are p, κv, and κh. The number of child deaths from resistant
infection is particularly sensitive to p and as p increases, that number decreases. κv, and κh
are measures of the competitive disadvantage of the resistant strain. As they increase towards 1
(so the competitive disadvantage decreases), the resistant infections and resistant deaths increase
significantly.
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(a) Adult, 1 Year (b) Adult, 5 Years
Figure 22: Note that as time increases, the sensitivity to p, κv, and κh decrease. Each parameter
has a doublet of bars representing the PRCC values for sensitive and resistant infections.
6 Discussion and Conclusion
There are a few general patterns in our simulations. First, using a short half-life treatment drug,
assumed here to be effective against both sensitive and resistant symptomatic infections, decreases
the advantage of the resistant strain, so also reduces the dependence of resistant emergence on IPT.
Second, all the results are highly sensitive to p and the value of p at which the resistant strain
dominates depends on whether it’s a low or high transmission region. There are strong non-linear
relationships between p, c, and the IPT and treatment drug half-lives. There are bifurcations
in realistic parameter regimes that suggest IPT should be applied with caution and with a good
knowledge of the background levels of resistance in the region. Finally, we specifically considered
both short- and long-range results (1 - 10 years) to inform the sustainability of current IPT and
treatment programs. Particularly as new drugs are not quickly developed, it will be important to
know if our current protocols will result in high levels of resistance in the future.
In the high transmission region, successful invasion of resistant strains is mostly driven by the
drug(s) used for symptomatic treatment. Over the first year, IPT has a 0.1%-5% effect (both
increases and reductions) on the total number of deaths from malaria for all scenarios. When a
short half-life drug such as AL or ACT is used for treatment, IPT usage always results in lives
saved with a 16.5%-18.5% reduction in total child deaths over 5 years (around 4,500-5,000 lives
saved). However, when a long half-life drug such as SP is used for symptomatic treatment, use of
IPT results range from a 13% increase in deaths to an 8.5% decrease in deaths over 5 years (from
2,900 additional deaths to 1,000 lives saved). When resistance to the treatment drug is high (p is
low) then IPT use results in faster takeover of the resistant strain, thus causing in more deaths.
Initially, one would then recommend using a short half-life treatment drug whenever possible while
applying IPT with a long half-life drug such as SP.
However, it is important to note the effect that the half-life of the symptomatic treatment drug
has on total number of deaths. In particular, a short half-life treatment drug gives very similar total
number of deaths across the resistance level spectrum, from partially to nearly fully resistant. The
long half-life drug used as treatment gives order of magnitude differences in total deaths depending
on the level of resistance. When p = 0.10 (resistance is high), there are 119,000 total deaths over 5
years, whereas when p = 0.50 (low resistance) there are about 11,000 deaths over 5 years. For the
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short half-life treatment drug scenario, the total number of deaths over 5 years is about 17,000 for
all levels of resistance considered and thus gives much lower number of deaths than the long/long
scenario for highly resistant strains, but higher total deaths if resistance is weak.
The take-home message is that (1) treatment drugs are generally driving resistance in high
transmission areas and the role of IPT in driving resistance tends to be minor comparatively, (2)
however, when a highly resistant strain is circulating, IPT can indeed result in increased levels of
resistance and loss of lives, particularly over longer time periods, and (3) in general, when short
half-life drugs such as AL or ACT are used for treatment and SP is used for IPT, as is currently the
case, regular use of IPT in children will result in potentially thousands of lives saved over the course
of 5 to 10 years. We point out that the dynamics can be complex, so there are levels of resistance for
which IPT saves lives over a short time period, but results in a cumulative loss of lives over 5-10 year
periods as resistance levels ramp up. Therefore, our model suggests caution in using IPT without a
corresponding heightened surveillance and awareness of changes in the circulating resistant strains
over time. If resistance were to be significantly increasing over time, then evaluation of both the
treatment drug and IPT usage would be warranted. Finally, we measured the effectiveness of IPT in
lives saved. There may also be other benefits, such as a shortened length of asymptomatic malaria
infections, that are not measured here.
In low transmission regions, we see different patterns in the costs and benefits of IPT. Here,
IPT can have a much larger role in driving resistance when highly resistant strains are circulating.
For example, in the long/long scenario with a highly resistant strain circulating, the proportion of
resistant cases stays low when IPT is not used, but rises to over 70% in children over the course of
10 years when IPT is used (Figure 13). For the long/short scenario, IPT also results in an increase
in proportion resistant that would not otherwise occur, but at a greatly reduced rate of increase
(Figure 14). However, for all but the most highly resistant strains, IPT usage in low transmission
regions results in lives saved and does not drive take over of resistant strains. IPT generally results
in a 24-26% reduction in deaths in the long/long scenario over 5 years (about 120 lives saved) and
in 26-29% decrease in deaths for the long/short scenario over 5 years (about 140 lives saved). Thus,
in general, it is better to use the short half-life treatment drug with a long half-life IPT in the low
transmission regions. Although it is not as critical as in the high transmission regions, our model
does suggest some caution and an increased awareness of circulating resistant strains is warranted
when IPT is used in a low transmission region.
A more complete cost/benefit analysis that includes cost of IPT and treatment drugs per dose,
total number of doses needed, and a broader definition of benefits including not only deaths averted
but severe and asymptomatic cases averted and reductions in total time infected would be interesting.
We have not considered how IPT might directly change the age at which children gain the “mature”
status based on a combination of many previous exposures to malaria and general improvement in
the immune system due to age. Effective use of IPT could in fact increase that age, resulting in
more serious cases of malaria in older than usual children. This could result again in increases of
deaths or serious disease in what we are now calling the mature age group. We have focused solely
on the use of SP as the IPT drug while varying the drugs used for treatment. While this is generally
true currently, considering additional drugs for potential use as IPT could be useful. We are looking
at holoendemic regions with no seasonality (year-round transmission) and it would be interesting to
extend to regions with seasonal malaria transmission.
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AValley bot-
tom
Middle Hill Hilltop Asymp.
Prevalence
Altitude in meters 1430 1500 1580
(Village) (Iguhu) (Makhokho) (Sigalagala)
Duration (in
months) of
parasitemia by age
Age 5-9 6 4 3 34.4 %
Age 10-14 6 4 3 34.1 %
Age >14 1 1 1 9.1%
% asymptomatic by
region
52.4% 23.3%
% of vectors found
in region
98% 1% 1%
% of 334
asymptomatic
episodes in region
44% 24.9% 31.1%
Table 9: Duration (in months) of asymptomatic parasitemia by age and microgeographic locale;
prevalence of asymptomatic malaria by age and region; and percent of vector population found in
each locale. This region is considered hypoendemic. 15% of asymptomatic episodes lasted 1 month.
38.1% of episodes lasted 2-5 months and 14.2% of episodes lasted 6-12 months. 32.5% experienced
no infection episode. Note: Iguhu is near the Yala River, a major breeding site for An. gambiae
mosquitoes [3].
B Basic reproductive numbers
The basic reproductive numbers for the sensitive parasite strain Rs and the resistant parasite strain
Rr were computed using the next generation matrix. The next generation matrix (NGM) is
K =
(
0 K1,2
K2,1 0
)
,
where
K1,2 =

βhλS0
µmN0
0 0 0 0 0
βh(1−λ)S0
µmN0
0 0 0 0 0
0 βhkhλ(S0+T0)µmN0 0 0 0 0
0 βhkh(1−λ)(S0+T0)µmN0 0 0 0 0
βhλ
′Sm0
µmN0
0 0 0 0 0
βh(1−λ′)Sm0
µmN0
0 0 0 0 0
0
βhkhλp(Sm0+Tm0)
µmN0
0 0 0 0
0 βhkh(1−λ
′)(Sm0+Tm0)
µmN0
0 0 0 0

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and
K2,1 =

k9,1 k9,2 0 0 k9,5 k9,6 0 0
0 0 k10,3 k10,4 0 0 k10,7 k10,8
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0

k9,1 =
βmSv0
N0
(
1 +
η
Ams
)
k9,2 =
βmSv0
AaN0
(
1 +
ν
As
+
η(Amaν +Asν
′)
AsAmsAma
+
η
Ama
)
k9,5 =
βmSv0
AmsN0
k9,6 =
βmSv0
AmaN0
(
1 +
ν′
Ams
)
k10,3 =
βmkmSv0
BsN0
(
1 +
η
Bms
)
k10,4 =
βmkmSv0
BaN0
(
1 +
η(Amaν +Bsν
′)
BsAmaBms
+
ηkm
Ama
+
ν
Bs
)
k10,7 =
βmkmSv0
BmsN0
k10,8 =
bmkmSv0
AmaN0
(
1 +
ν′
Bms
)
In addition to the next generation matrix approach, the reproductive numbers were derived
based on the biological interpretation of the model.
Sensitive reproduction number Rs
Let Rnaives−asym and Rnaives−sym denote the reproduction numbers for the sensitive strain of infection
associated with asymptomatic and symptomatic cases in naive humans, respectively. Let Rmatures−asym
and Rmatures−sym denote the reproduction numbers for the sensitive strain of infection associated with
asymptomatic and symptomatic cases, in mature humans respectively.
At the beginning of an outbreak the proportion of the population susceptible to the sensitive
parasite is S0 + Sm0. A portion of this sensitive population will become asymptomatically infected
and either remain asymptomatic or transition to a symptomatic case (there is no transition from
symptomatic to asymptomatic in this model). A portion of these infected individuals will age into
the mature population. The sensitive reproductive number for the asymptomatic cases in the naive
population over the full course of infection, i.e., the number of naive human asymptomatic cases
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resulting from one initially sensitive case, is then given by
Rnaives−asym = (1− λ)︸ ︷︷ ︸
fraction that
are asym.
(βm)︸ ︷︷ ︸
trans. rate
to vectors
[
1
Aa︸︷︷︸
duration of
naive asym.
+
ν
Aa︸︷︷︸
fraction that
become sym.
(
1
As︸ ︷︷ ︸
duration of
naive sym.
+
( η
As
)
︸ ︷︷ ︸
fraction of
sym. that age
( 1
Ams
))
︸ ︷︷ ︸
duration of
mature sym.
+
( η
Aa
)
︸ ︷︷ ︸
fraction of
asym. that age
(
1
Ama︸ ︷︷ ︸
duration of
mature asym.
+
ν′
Ama︸ ︷︷ ︸
fraction that
become sym.
( 1
Ams
))]
︸ ︷︷ ︸
duration of
mature sym.
(βh)︸︷︷︸
trans. rate
to hosts
(
Sv0
N0
)
︸ ︷︷ ︸
vector to
host ratio
(
1
µm
)
︸ ︷︷ ︸
duration of
vector infection
(
S0
N0
)
︸ ︷︷ ︸
susceptible
proportion
The sensitive symptomatic reproductive number for the naive population, or the number of naive
human cases resulting from one initial symptomatic individual, is given by
Rnaives−sym = λ︸︷︷︸
fraction that
are sym.
(βm)︸ ︷︷ ︸
trans. rate
to vectors
(( 1
As
)
︸ ︷︷ ︸
duration of
naive sym.
+
( η
As
)
︸ ︷︷ ︸
fraction of
sym. that age
( 1
Ams
))
︸ ︷︷ ︸
duration of
mature sym.
(βh)︸︷︷︸
trans. rate
to hosts
(
Sv0
N0
)
︸ ︷︷ ︸
vector to
host ratio
(
1
µm
)
︸ ︷︷ ︸
duration of
vector infection
(
S0
N0
)
.︸ ︷︷ ︸
susceptible
proportion
The sensitive reproductive number for the asymptomatic cases in the mature population over the
full course of infection, i.e., the number of mature human asymptomatic cases resulting from one
initially sensitive case, is then given by
Rmatures−asym = (1− λ′)︸ ︷︷ ︸
fraction that
are asym.
(βm)︸ ︷︷ ︸
trans. rate
to vectors
( ( 1
Ama
)
︸ ︷︷ ︸
duration of
mature asym.
+
( ν′
Ama
)
︸ ︷︷ ︸
fraction that
become sym.
( 1
Ams
)
︸ ︷︷ ︸
duration of
mature sym.
)
(βh)︸︷︷︸
trans. rate
to hosts
(
Sv0
N0
)
︸ ︷︷ ︸
vector to
host ratio
(
1
µm
)
︸ ︷︷ ︸
duration of
vector infection
(
Sm0
N0
)
︸ ︷︷ ︸
susceptible
proportion
The sensitive symptomatic reproductive number for the mature population, or the number of mature
human cases resulting from one initial symptomatic individual, is given by
Rmatures−sym = λ′︸︷︷︸
fraction that
are sym.
(βm)︸ ︷︷ ︸
trans. rate to
vectors
(
1
Ams
)
︸ ︷︷ ︸
duration of
mature sym.
(βh)︸︷︷︸
trans. rate to
hosts
(
Sv0
N0
)
︸ ︷︷ ︸
vector to
host ratio
(
1
µm
)
︸ ︷︷ ︸
duration of
vector infection
(
Sm0
N0
)
.︸ ︷︷ ︸
susceptible
proportion
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Then, the reproduction number for the sensitive strain of infection takes the following form:
R2s = Rnaives−asym +Rnaives−sym +Rmatures−asym +Rmatures−sym
=
βmβhS0Sv0
µmN20
[
1− λ
Aa
+
ν(1− λ)
AaAs
+
ην(1− λ)
AaAmsAs
+
η(1− λ)
AaAma
+
ην′(1− λ)
AaAmaAms
+
λ
As
+
ηλ
AsAms
]
+
βmβhSm0Sv0
µmN20
[
1− λ′
Ama
+
ν′(1− λ′)
AmaAms
+
ν′
Ams
]
.
(11)
The above reproduction number Rs was also computed using the next generation matrix approach.
Resistant reproduction number Rr
Let Rnaiver−asym and Rnaiver−sym denote the reproduction numbers for the resistant strain of infection
associated with asymptomatic and symptomatic cases in naive humans, respectively. Let Rmaturer−asym
and Rmaturer−sym denote the reproduction numbers for the resistant strain of infection associated with
asymptomatic and symptomatic cases, in mature humans respectively.
At the beginning of an outbreak the proportion of the population susceptible to the resistant
parasite is S0 + Sm0 + T0 + Tm0. The resistant reproductive number for the asymptomatic cases in
the naive population over the full course of infection, i.e., the number of naive human asymptomatic
cases resulting from one initially resistant case, is then given by
Rnaiver−asym = (1− λ)︸ ︷︷ ︸
fraction that
are asym.
(βmκm)︸ ︷︷ ︸
trans. rate
to vectors
[
1
Ba︸︷︷︸
duration of
naive asym.
+
ν
Ba︸︷︷︸
fraction that
become sym.
(
1
Bs︸ ︷︷ ︸
duration of
naive sym.
+
( η
Bs
)
︸ ︷︷ ︸
fraction of
sym. that age
( 1
Bms
))
︸ ︷︷ ︸
duration of
mature sym.
+
( η
Ba
)
︸ ︷︷ ︸
fraction of
asym. that age
(
1
Ama︸ ︷︷ ︸
duration of
mature asym.
+
ν′
Ama︸ ︷︷ ︸
fraction that
become sym.
( 1
Bms
))]
︸ ︷︷ ︸
duration of
mature sym.
(βhκh)︸ ︷︷ ︸
trans. rate
to hosts
(
Sv0
N0
)
︸ ︷︷ ︸
vector to
host ratio
(
1
µm
)
︸ ︷︷ ︸
duration of
vector infection
(
S0 + T0
N0
)
︸ ︷︷ ︸
susceptible
proportion
The resistant symptomatic reproductive number for the naive population, or the number of naive
human cases resulting from one initial symptomatic individual, is given by
Rnaiver−sym = λ︸︷︷︸
fraction that
are sym.
(βmκm)︸ ︷︷ ︸
trans. rate
to vectors
(( 1
Bs
)
︸ ︷︷ ︸
duration of
naive sym.
+
( η
Bs
)
︸ ︷︷ ︸
fraction of
sym. that age
( 1
Bms
))
︸ ︷︷ ︸
duration of
mature sym.
(βhκh)︸ ︷︷ ︸
trans. rate
to hosts
(
Sv0
N0
)
︸ ︷︷ ︸
vector to
host ratio
(
1
µm
)
︸ ︷︷ ︸
duration of
vector infection
(
S0 + T0
N0
)
.︸ ︷︷ ︸
susceptible
proportion
The resistant reproductive number for the asymptomatic cases in the mature population over the
full course of infection, i.e., the number of mature human asymptomatic cases resulting from one
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initially resistant case, is then given by
Rmaturer−asym = (1− λ′)︸ ︷︷ ︸
fraction that
are asym.
(βmκm)︸ ︷︷ ︸
trans. rate
to vectors
( ( 1
Ama
)
︸ ︷︷ ︸
duration of
mature asym.
+
( ν′
Ama
)
︸ ︷︷ ︸
fraction that
become sym.
( 1
Bms
)
︸ ︷︷ ︸
duration of
mature sym.
)
(βhκh)︸ ︷︷ ︸
trans. rate
to hosts
(
Sv0
N0
)
︸ ︷︷ ︸
vector to
host ratio
(
1
µm
)
︸ ︷︷ ︸
duration of
vector infection
(
Sm0 + Tm0
N0
)
︸ ︷︷ ︸
susceptible
proportion
The resistant symptomatic reproductive number for the mature population, or the number of mature
human cases resulting from one initial symptomatic individual, is given by
Rmaturer−sym = λ′︸︷︷︸
fraction that
are sym.
(βmκm)︸ ︷︷ ︸
trans. rate to
vectors
(
1
Bms
)
︸ ︷︷ ︸
duration of
mature sym.
(βhκh)︸ ︷︷ ︸
trans. rate to
hosts
(
Sv0
N0
)
︸ ︷︷ ︸
vector to
host ratio
(
1
µm
)
︸ ︷︷ ︸
duration of
vector infection
(
Sm0 + Tm0
N0
)
.︸ ︷︷ ︸
susceptible
proportion
Then, the reproduction number for the resistant strain of infection takes the following form:
R2r = Rnaiver−asym +Rnaiver−sym +Rmaturer−asym +Rmaturer−sym
=
κmβmκhβh(S0 + T0)Sv0
µmN20
[
1− λ
Ba
+
ν(1− λ)
BaBs
+
ην(1− λ)
BaBmsBs
+
η(1− λ)
BaAma
+
ην′(1− λ)
BaAmaBms
+
λ
Bs
+
ηλ
BsBms
]
+
κmβmκhβh(Sm0 + Tm0)Sv0
µmN20
[
1− λ′
Ama
+
ν′(1− λ′)
AmaBms
+
ν′
Bms
]
.
(12)
The above reproduction number Rr was also computed using the next generation matrix approach.
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